Pages that link to "Q72657219"
Jump to navigation
Jump to search
The following pages link to Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia (Q72657219):
Displaying 50 items.
- An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes (Q24622700) (← links)
- Decitabine in the treatment of myelodysplastic syndromes (Q24641906) (← links)
- GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells (Q28477278) (← links)
- SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response (Q33331870) (← links)
- Clinical development of demethylating agents in hematology (Q34395179) (← links)
- Aberrant DNA methylation in malignant melanoma (Q34516587) (← links)
- Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies (Q34768789) (← links)
- Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. (Q35164242) (← links)
- Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. (Q35183982) (← links)
- Cancer epigenetics (Q35551103) (← links)
- Development of the risk of infection in the child with leukemia (Q35805779) (← links)
- Investigational agents in myeloid disorders (Q35909283) (← links)
- RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia (Q36015018) (← links)
- Decitabine: a historical review of the development of an epigenetic drug (Q36284232) (← links)
- Inhibitors of DNA methylation: beyond myelodysplastic syndromes (Q36338036) (← links)
- p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies (Q36848202) (← links)
- p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. (Q36890276) (← links)
- Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors (Q36900856) (← links)
- Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. (Q37022672) (← links)
- Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias (Q37184917) (← links)
- Epigenetic therapy of leukemia: An update (Q37307226) (← links)
- Therapy with azanucleosides for myelodysplastic syndromes (Q37765469) (← links)
- Pharmacokinetic evaluation of decitabine for the treatment of leukemia (Q37866296) (← links)
- Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer (Q38529787) (← links)
- Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells (Q38742600) (← links)
- Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected]. (Q39102674) (← links)
- UBC and YWHAZ as suitable reference genes for accurate normalisation of gene expression using MCF7, HCT116 and HepG2 cell lines (Q39136279) (← links)
- MYC-Master Regulator of the Cancer Epigenome and Transcriptome (Q39306981) (← links)
- Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response (Q40419898) (← links)
- The importance of the specific Z-DNA structure and polyamines in carcinogenesis: Fact or fiction (Q41131287) (← links)
- 3-Deazauridine (NSC 126849): an interesting modulator of biochemical response (Q41368389) (← links)
- DNA methylation as a target for drug design (Q41730013) (← links)
- Transbuccal delivery of 5-aza-2 -deoxycytidine: effects of drug concentration, buffer solution, and bile salts on permeation (Q41966277) (← links)
- A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. (Q42371209) (← links)
- Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. (Q43247519) (← links)
- Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides (Q43507381) (← links)
- Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study (Q43731616) (← links)
- Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer (Q43822201) (← links)
- Effect of cytidine analogs on cell growth and differentiation on a human neuroblastoma line (Q43860783) (← links)
- Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells (Q44349057) (← links)
- 5-AZA-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation (Q45117672) (← links)
- Treatment with a DNA methyltransferase inhibitor feminizes zebrafish and induces long-term expression changes in the gonads. (Q47568000) (← links)
- Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine. (Q54369162) (← links)
- Growth inhibitory effects of 5-aza-2'-deoxycytidine in HL-60 promyelocytic leukemia cells resistant to differentiation induction. (Q54418210) (← links)
- Cell cycle effects and cellular pharmacology of 5-AZA-2?-deoxycytidine (Q54485278) (← links)
- Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression. (Q54527773) (← links)
- Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase (Q67535912) (← links)
- Cytotoxicity of 5-aza-2'-deoxycytidine in a mammalian cell system (Q67536246) (← links)
- Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2′-deoxycytidine against human leukemic cells of different phenotype (Q67675052) (← links)
- Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside (Q72697348) (← links)